CYV

CERYVYN FPO [CYV]
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0110 -8.3%

Updated 3 Sep 2026 · Signals refresh every scan

⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Get alerts when CYV triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track CYV — Free

Active Signals

Bullish Signals

  • RSI is looking oversold — historically a spot where stocks tend to bounce
  • Volume surging at 3.9x normal while price falls — heavy selling pressure
  • On a tear — up 10.0% over the last 5 days
  • Lagging the Small Ords index — relative strength of 0.86, underperforming its peers
  • Critical cash runway (1.0 quarters)
  • 4C filed 2026-07-26
  • Revenue in sharp decline (-100%)
  • Near 52-week low (0% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (1 events)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 98% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.12%/day)
  • Pre-revenue company — Altman Z-Score not applicable
  • Penny stock risk ($0.012)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -100% — the top line is shrinking
Ask Scout AI about CYV
"What's driving CYV today?" "How does CYV compare to peers?" "Key risks for CYV?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Proposed issue of securities - CYV
NONE Appendix 4G and Corporate Governance Statement
NONE Notification regarding unquoted securities - CYV
LOW Appendix 4E and 2026 Annual Report
LOW Quarterly Activities/Appendix 4C Cash Flow Report

Recent ASX Announcements

2026-09-01 Proposed issue of securities - CYV
2026-08-31 Appendix 4G and Corporate Governance Statement
2026-08-31 Appendix 4E and 2026 Annual Report PRICE SENSITIVE
2026-08-21 Notification regarding unquoted securities - CYV
2026-07-26 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE

Key Metrics

$16.4M
Market Cap
4.7M
Avg Volume
3.9x
Vol Ratio
$0.01 — $0.60
52-Week Range
0.3%
Short Interest
1 qtrs
Cash Runway
N/A
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSneutralEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 82%
LLeader vs LaggardlaggardRS: -11
IInstitutional SponsorshipweakInst: 5%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:CYV vs REGCYV vs CANCYV vs BIT
Scout Pro — Deeper Analysis for CYV
Try Pro free for 30 days
Share this analysis

Track CYV and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required